Table 1.
Demographics and baseline characteristics of the patients.
| Characteristic | Treatment group (n = 271) | Control group (n = 272) | P |
|---|---|---|---|
| Age (years)† | 42.36 ± 11.23 | 39.61 ± 12.40 | 0.631 |
| Male, n (%) | 188 (69.89) | 162 (62.79) | 0.31 |
| Duration of illness (years)† | 11.17 ± 6.22 | 10.7 ± 6.28 | 0.43 |
| MTCT, n (%) | 63 (23.42) | 49 (18.99) | 0.52 |
| Family history, n (%) | 99 (36.8) | 82 (31.78) | 0.29 |
| Smoking, n (%) | 25 (9.29) | 26 (10.08) | 0.78 |
| Alcohol consumption, n (%) | 38 (14.13) | 28 (10.85) | 0.534 |
| BMI† | 24.08 ± 14.98 | 24.06 ± 13.04 | 0.99 |
| ALT (U/L)† | 73.31 ± 15.42 | 72.65 ± 16.29 | 0.68 |
| AST (U/L)† | 49.51 ± 19.21 | 51.93 ± 20.08 | 0.31 |
| HBsAg (lg IU/mL)† | 3.15 ± 0.59 | 3.12 ± 0.67 | 0.87 |
| HBV DNA (lg IU/mL)† | 6.90 ± 1.31 | 6.84 ± 1.45 | 0.82 |
| cccDNA (lg IU/mL)† | 8.89 ± 3.22 | 9.10 ± 3.35 | 0.77 |
| HBV genotypes | 0.312 | ||
| B | 113 (42.8) | 139 (48.4) | |
| C | 152 (56.5) | 144 (50.2) | |
| D | 0 (0) | 1 (0.3) | |
| G | 2 (0.7) | 3 (1.0) | |
| kPa score† | 9.99 ± 6.97 | 10.16 ± 8.16 | 0.719 |
| Grade of necroinflammation | 0.733 | ||
| G1 | 5 (5.7) | 7 (7.7) | |
| G1–2 | 0 (0) | 1 (1.1) | |
| G2 | 71 (80.7) | 72 (79.1) | |
| G2–3 | 2 (2.3) | 1 (1.1) | |
| G3 | 10 (11.4) | 10 (11.0) | |
| Stage of fibrosis | 0.183 | ||
| S0 | 1 (1.1) | 0 (0.0) | |
| S1 | 16 (18.2) | 21 (23.3) | |
| S1–2 | 1 (1.1) | 2 (2.2) | |
| S2 | 49 (55.7) | 54 (60.0) | |
| S2–3 | 1 (1.1) | 1 (1.1) | |
| S3 | 20 (22.7) | 9 (10.0) | |
| S4 | 0 (0.0) | 3 (3.3) |
Values in parentheses are percentages; †value is the mean ± standard deviation. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; MTCT, mother-to-child transfection.